Elevated pre-operative neutrophil to lymphocyte ratio predicts disease free survival following pancreatic resection for periampullary carcinomas

Pancreatology. 2013 Sep-Oct;13(5):534-8. doi: 10.1016/j.pan.2013.07.283. Epub 2013 Jul 31.

Abstract

Background: The pre-operative neutrophil-to-lymphocyte ratio (NLR), when ≥5 has been associated with reduced survival for patients with various gastrointestinal tract cancers, however, it's prognostic value in patients with periampullary tumour has not been reported to date.

Objectives: To determine the prognostic value of pre-operative NLR in terms of survival and recurrence of resected periampullary carcinomas.

Methods: This was a retrospective cohort study of consecutive patients undergoing pancreatoduodenectomy (PD) for periampullary carcinoma (pancreatic, ampullary, cholangiocarcinoma) identified from a departmental database. The effect of NLR upon survival and recurrence was explored.

Results: Overall median survival amongst 228 patients was 24 months (inter-quartile range [IQR]: 12-43). The median survival for those whose NLR was <5 was not significantly greater than those patients whose NLR was ≥5 (24 months [IQR: 14-42] versus 13 months [IQR: 8-48], respectively; p = 0.234). However, for those that developed recurrence, survival was greater in those with an NLR <5 at (20 months [IQR: 12-27] versus 11 months [IQR: 7-22], respectively; p = 0.038). This effect was most marked in those patients with cholangiocarcinoma (p = 0.019) whilst a trend to worse survival was seen in those with pancreatic adenocarcinoma. No effect was seen in patients with ampullary carcinoma (p = 0.516).

Conclusions: This study provides further evidence that pre-operative NLR offers important prognostic information regarding disease-free survival. This effect, however, is dependent upon the tumour type amongst patients undergoing PD.

Keywords: Disease-free survival; Neutrophil–lymphocyte ratio; Pancreatoduodenectomy; Periampullary carcinoma.

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / surgery
  • Aged
  • Cholangiocarcinoma / mortality
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphocyte Count*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / mortality
  • Neutrophils / pathology*
  • Pancreatic Neoplasms / mortality*
  • Pancreatic Neoplasms / surgery
  • Pancreaticoduodenectomy*
  • Prognosis
  • Retrospective Studies